p53 and vascular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma

International Journal of Cancer

Volumn 89, Issue 1, 2000, Pages 51-62

  Linderholm, Barbro ^a   Lindh, Birgitta ^a   Tavelin, Björn ^a   Grankvist, Kjell ^a   Henriksson, Roger ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; THROMBOSPONDIN 1; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; BREAST CARCINOMA; CANCER SURVIVAL; CORRELATION FUNCTION; DOWN REGULATION; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MUTATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK ASSESSMENT;

BREAST NEOPLASMS; ENDOTHELIAL GROWTH FACTORS; FEMALE; HUMANS; LYMPHOKINES; MULTIVARIATE ANALYSIS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0034688125     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(20000120)89:1<51::AID-IJC9>3.0.CO;2-8     Document Type: Article

References (25)

1. AGANI, F., KIRSCH, D.G., FRIEDMAN, S.L., KASTAN, M.B. and SEMENZA, G.L., p53 does not repress hypoxia-induced transcription of the vascular-endothelial-growth-factor gene. Cancer Res., 57, 4474-4477 (1997).
2. AXELSSON, K., LJUNG, B.M., MOORE II, D.H., THOR, A.D., CHEW, K.L., EDGRETON, S.M., SMITH, H.S. and MAYALL, B.H., Tumour angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J. nat. Cancer Inst., 87, 997-1008 (1995).
3. BERGH, J., NORBERG, T., SJÖGREN, S., LINDGREN, A. and HOLMBERG, L., Complete sequencing of the p53 gene provides prognostic information in breast-cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nature Med., 1, 1029-1034 (1995).
4. BORG, Å., LENNERSTRAND, J., STENMARK-ASKMALM, M., FERNO, M., BRISFORS, A., OHRVIK, A., STAL, O., KILLANDER, D., LANE, D. and BRUNDELL, J., Prognostic significance of p53 over-expression in primary breast cancer; a novel luminometric immunoassay applicable on steroid-receptor cytosols. Brit. J. Cancer, 71, 1013-1017 (1995).
5. DAMERON, K.M., VOLPERT, O.V., TAINSKY, M.A. and BOUCK, N., Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science, 265, 1582-1584 (1994).
6. ELLEDGE, R.M., Prognostic and predictive value of p53 and p21 in breast cancer. Breast Cancer Res. Treat., 52, 79-98 (1998).
7. FONTANINI, G., VIGNATI, S., LUCCHI, M., MUSSI, A., CALCINAI, A., BOLDRINI, L., CHINÉ, S., SILVESTRI, V., ANGELETTI, C.A., BASOLO, F. and BEVILACQUA, G., Neo-angiogenesis and p53 protein in lung cancer: their prognostic role and their relation with vascular-endothelial-growth-factor (VEGF) expression. Brit. J. Cancer, 75, 1295-1301 (1997).
8. FOX, S.B., LEEK, R.D., SMITH, K., HOLLYER, J., GREENALL, M. and HARRIS, A.L., Tumour angiogenesis in node-negative breast carcinomas - relationship with epidermal-growth-factor-receptor and survival. Breast Cancer Res. Treat., 29, 109-116 (1994).
9. GAGLIARDI, A. and COLLINS, D.C., Inhibition of angiogenesis by anti-estrogens. Cancer Res., 53, 533-535 (1993).
10. GANNON, J.V., GREAVES, R., IGGO, R. and HOWLEY, P.M., Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J., vol. 9. 1595-1602 (1990).
11. GASPARINI, G., BARBARESCHI, M., BORACCHI, P., VERDERIO, P., CAFFO, O., MELI, S., PALMA, P.D., MARUBINI, E. and BEVILACQUA, P., Tumour angio-genesis predicts clinical outcome of node-positive breast-cancer patients treated with adjuvant hormone therapy or chemotherapy. The Cancer Journal, 1, 131-141 (1995).
12. GASPARINI, G. and 12 OTHERS, Prognostic significance of vascular-endothelial-growth-factor protein in node-negative breast carcinoma. J. nat. Cancer Inst., 89, 139-147 (1997).
13. GASPARINI, G., WEIDNER, N. and BEVILACQUA, P., Intratumoral microvessel density and p53 protein: correlation with metastasis in head-and-neck squamous-cell carcinoma. Int. J. Cancer, 55, 739-744 (1993).
14. GASPARINI, G., WEIDNER, N., BEVILACQUA, P., MALUTA, S., DALLA PALMA, P., CAFFO, O., BARBARESCHI, M., BORACCHI, P., MARUBINI, E. and POZZA, F., Tumour microvessel density, p53 expression, tumour size and peritumoral lymphatic-vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J. clin. Oncol., 12, 454-466 (1994).
15. KIESER, A., WEICH, H.A., BRANDNER, G., MARME, D. and KOLCH, W., Mutant p53 potentiates protein-kinase-C induction of vascular-endothelial-growth-factor expression. Oncogene, 9, 963-969 (1994).
16. KOVACH, J., HARTMANN, A., BLASZYK, H., CUNNINGHAM, J., SCHAID, D. and SOMMER, S., Mutations detection by highly sensitive methods indicates that p53-gene mutations in breast cancer can have important prognostic value. Proc. Acad. Sci. (Wash.), 93, 1093-1096 (1996).
17. LANE, D., p53, guardian of the genome. Nature (Lond.), 358, 15-16 (1992).
18. 165) is of high prognostic value in node-negative breast carcinoma. J. clin. Oncol., 16, 3121-3128 (1998).
19. MUKHOPADHYAY, D., TSIOKAS, L. and SUKHATME, V.P., Wild-type p53 and v-Src exert opposing influences on human vascular-endothelial-growth-factor-gene expression. Cancer Res., 55, 6161-6165 (1995).
20. SCOTT, P.A.E., SMITH, K., POULSOM, R., DE BENEDETTI, A., BICKNELL, R. and HARRIS, A.L., Differential expression of vascular-endothelial-growth-factor mRNA vs. protein isoform expression in human breast cancer and relationship to eIF-4E. Brit. J. Cancer, 77, 2120-2128 (1998).
21. SILVESTRINI, R., BENINI, E., DAIDONE, M.G., VENERONI, S., BORACCHI, P., CAPPELLETTI, V., DI FRONZO, G. and VERONESI, U., p53 as an independent marker of in lymph-node-negative breast-cancer patients. J. nat. Cancer Inst., 85, 965-970 (1993).
22. SJÖGREN, S., INGANÄS, M., NORBERG, T., LINDGREN, A., NORDGREN, H., HOLMBERG, L. and BERGH, J., The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J. nat. Cancer Inst., 88, 173-182 (1996).
23. TAKAHASHI, Y., BUCANA, C.D., CLEARY, K.R. and ELLIS, L.M., p53, vessel count, and vascular-endothelial-growth-factor expression in human colon cancer. Int. J. Cancer, 79, 34-38 (1998).
24. TOI, M., GION, M., BIGANZOLI, E., DITTADI, R., BORACCHI, P., MICELI, R., MELI, S., MORI, K., TOMINAGA, T. and GASPARINI, G., Co-determination of the angiogenic factors thymidine phosphorylase and vascular endothelial growth factor (VEGF) in human breast cancer: prognostic implications. Angiogenesis, 1, 71-83 (1997).
25. YIN, Y., TAINSKY, M.A., BISCHOFF, F.Z., STRONG, L.C. and WAHL, G.M., Wild-type p53 restores cell-cycle control and inhibits gene amplification in cell with mutant p53 alleles. Cell, 70, 937-948 (1992).